Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Serum uric acid and progression of diabetic nephropathy in type 1 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{f80d001399c64bfab385d66b5cfeeecc,
title = "Serum uric acid and progression of diabetic nephropathy in type 1 diabetes",
abstract = "AIMS: Uric acid (UA) is a risk factor for CKD. We evaluated UA in relation to change in GFR in patients with type 1 diabetes.METHODS: Post hoc analysis of a trial of losartan in diabetic nephropathy, mean follow-up 3 years (IQR 1.5-3.5). UA was measured at baseline. Primary end-point was change in measured GFR. UA was tested in a linear regression model adjusted for known progression factors (gender, HbA1c, systolic blood pressure, cholesterol, baseline GFR and baseline urinary albumin excretion rate (UAER)).RESULTS: Baseline UA was 0.339 mmol/l (SD ±0.107), GFR 87 ml/min/1.73 m2(±23), geometric mean UAER 1023 mg/24 h (IQR, 631 - 1995). Mean rate of decline in GFR was 4.6 (3.7) ml/min/year. In the upper quartile of baseline UA the mean decline in GFR from baseline to the end of the study was 6.2 (4.9) ml/min/1.73 m2and 4.1 (3.1) ml/min/1.73 m2in the three lower quartiles of UA, (p = 0.088). In a linear model including baseline covariates (UAER, GFR, total cholesterol, HDL cholesterol) UA was associated with decline in GFR (r2 = 0.45, p < 0.001).CONCLUSION: Uric acid was weakly associated with decline in GFR in type 1 diabetic patients with overt nephropathy.",
keywords = "Journal Article",
author = "S Pilemann-Lyberg and M Lindhardt and Frederik Persson and S Andersen and P Rossing",
note = "Copyright {\textcopyright} 2018. Published by Elsevier Inc.",
year = "2018",
month = may,
day = "1",
doi = "10.1016/j.jdiacomp.2018.02.002",
language = "English",
volume = "32",
pages = "470--473",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc",
number = "5",

}

RIS

TY - JOUR

T1 - Serum uric acid and progression of diabetic nephropathy in type 1 diabetes

AU - Pilemann-Lyberg, S

AU - Lindhardt, M

AU - Persson, Frederik

AU - Andersen, S

AU - Rossing, P

N1 - Copyright © 2018. Published by Elsevier Inc.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - AIMS: Uric acid (UA) is a risk factor for CKD. We evaluated UA in relation to change in GFR in patients with type 1 diabetes.METHODS: Post hoc analysis of a trial of losartan in diabetic nephropathy, mean follow-up 3 years (IQR 1.5-3.5). UA was measured at baseline. Primary end-point was change in measured GFR. UA was tested in a linear regression model adjusted for known progression factors (gender, HbA1c, systolic blood pressure, cholesterol, baseline GFR and baseline urinary albumin excretion rate (UAER)).RESULTS: Baseline UA was 0.339 mmol/l (SD ±0.107), GFR 87 ml/min/1.73 m2(±23), geometric mean UAER 1023 mg/24 h (IQR, 631 - 1995). Mean rate of decline in GFR was 4.6 (3.7) ml/min/year. In the upper quartile of baseline UA the mean decline in GFR from baseline to the end of the study was 6.2 (4.9) ml/min/1.73 m2and 4.1 (3.1) ml/min/1.73 m2in the three lower quartiles of UA, (p = 0.088). In a linear model including baseline covariates (UAER, GFR, total cholesterol, HDL cholesterol) UA was associated with decline in GFR (r2 = 0.45, p < 0.001).CONCLUSION: Uric acid was weakly associated with decline in GFR in type 1 diabetic patients with overt nephropathy.

AB - AIMS: Uric acid (UA) is a risk factor for CKD. We evaluated UA in relation to change in GFR in patients with type 1 diabetes.METHODS: Post hoc analysis of a trial of losartan in diabetic nephropathy, mean follow-up 3 years (IQR 1.5-3.5). UA was measured at baseline. Primary end-point was change in measured GFR. UA was tested in a linear regression model adjusted for known progression factors (gender, HbA1c, systolic blood pressure, cholesterol, baseline GFR and baseline urinary albumin excretion rate (UAER)).RESULTS: Baseline UA was 0.339 mmol/l (SD ±0.107), GFR 87 ml/min/1.73 m2(±23), geometric mean UAER 1023 mg/24 h (IQR, 631 - 1995). Mean rate of decline in GFR was 4.6 (3.7) ml/min/year. In the upper quartile of baseline UA the mean decline in GFR from baseline to the end of the study was 6.2 (4.9) ml/min/1.73 m2and 4.1 (3.1) ml/min/1.73 m2in the three lower quartiles of UA, (p = 0.088). In a linear model including baseline covariates (UAER, GFR, total cholesterol, HDL cholesterol) UA was associated with decline in GFR (r2 = 0.45, p < 0.001).CONCLUSION: Uric acid was weakly associated with decline in GFR in type 1 diabetic patients with overt nephropathy.

KW - Journal Article

U2 - 10.1016/j.jdiacomp.2018.02.002

DO - 10.1016/j.jdiacomp.2018.02.002

M3 - Journal article

C2 - 29534864

VL - 32

SP - 470

EP - 473

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 5

ER -

ID: 53407483